Can plant-derived anti-HIV compounds be used in COVID-19 cases?
© 2022 The Author(s)..
People living with HIV are more exposed to the adverse health effects of the worldwide COVID-19 pandemic. The pandemic's health and social repercussions may promote drug abuse and inadequate HIV management among this demographic. The coronavirus pandemic of 2019 (COVID-19) has caused unprecedented disruption worldwide in people's lives and health care. When the COVID-19 epidemic was identified, people with HIV faced significant obstacles and hurdles to achieving optimal care results. The viral spike protein (S-Protein) and the cognate host cell receptor angiotensin-converting enzyme 2 (ACE2) are both realistic and appropriate intervention targets. Calanolides A, Holy Basil, Kuwanon-L, and Patentiflorin have anti-HIV effects. Our computational biology study investigated that these compounds all had interaction binding scores related to S protein of coronavirus of -9.0 kcal /mol, -7.1 kcal /mol, -9.1 kcal /mol, and -10.3 kcal/mol/mol, respectively. A combination of plant-derived anti-HIV compounds like protease inhibitors and nucleoside analogs, which are commonly used to treat HIV infection, might be explored in clinical trials for the treatment of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:166 |
|---|---|
| Enthalten in: |
Medical hypotheses - 166(2022) vom: 01. Sept., Seite 110926 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Das, Diptimayee [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 21.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.mehy.2022.110926 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344545350 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344545350 | ||
| 003 | DE-627 | ||
| 005 | 20231226023023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mehy.2022.110926 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344545350 | ||
| 035 | |a (NLM)35935095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Das, Diptimayee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Can plant-derived anti-HIV compounds be used in COVID-19 cases? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a People living with HIV are more exposed to the adverse health effects of the worldwide COVID-19 pandemic. The pandemic's health and social repercussions may promote drug abuse and inadequate HIV management among this demographic. The coronavirus pandemic of 2019 (COVID-19) has caused unprecedented disruption worldwide in people's lives and health care. When the COVID-19 epidemic was identified, people with HIV faced significant obstacles and hurdles to achieving optimal care results. The viral spike protein (S-Protein) and the cognate host cell receptor angiotensin-converting enzyme 2 (ACE2) are both realistic and appropriate intervention targets. Calanolides A, Holy Basil, Kuwanon-L, and Patentiflorin have anti-HIV effects. Our computational biology study investigated that these compounds all had interaction binding scores related to S protein of coronavirus of -9.0 kcal /mol, -7.1 kcal /mol, -9.1 kcal /mol, and -10.3 kcal/mol/mol, respectively. A combination of plant-derived anti-HIV compounds like protease inhibitors and nucleoside analogs, which are commonly used to treat HIV infection, might be explored in clinical trials for the treatment of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a ACE2, Angiotensin-converting enzyme-2 | |
| 650 | 4 | |a AIDS, Acquired immunodeficiency syndrome | |
| 650 | 4 | |a AZT, Azidothymidine | |
| 650 | 4 | |a CD4, Cluster of Differentiation 4 | |
| 650 | 4 | |a Calanolides A | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a HAART, Highly active antiretroviral therapy, ART, Antiretroviral therapy | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a HIV, Human Immunodeficiency Virus | |
| 650 | 4 | |a Holy Basil | |
| 650 | 4 | |a IN, Integrase | |
| 650 | 4 | |a Kuwanon-L | |
| 650 | 4 | |a NETs, neutrophil extracellular traps | |
| 650 | 4 | |a NNTRIs, Non-nucleoside analogs transcriptase reverse inhibitor | |
| 650 | 4 | |a NRTIs, nucleoside analog reverse transcriptase inhibitor | |
| 650 | 4 | |a Patentiflorin A | |
| 650 | 4 | |a RT, Reverse Transcriptase | |
| 650 | 4 | |a S protein | |
| 650 | 4 | |a SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 | |
| 700 | 1 | |a Bihari Jena, Atala |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, Antara |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar Radhakrishnan, Arun |e verfasserin |4 aut | |
| 700 | 1 | |a Duttaroy, Asim K |e verfasserin |4 aut | |
| 700 | 1 | |a Pathak, Surajit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical hypotheses |d 1983 |g 166(2022) vom: 01. Sept., Seite 110926 |w (DE-627)NLM00007487X |x 1532-2777 |7 nnns |
| 773 | 1 | 8 | |g volume:166 |g year:2022 |g day:01 |g month:09 |g pages:110926 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mehy.2022.110926 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 166 |j 2022 |b 01 |c 09 |h 110926 | ||